Quantum Genesis AI Corp. (OTC: QGAI), a biotechnology company specializing in enzyme engineering, molecular modeling, and biocatalysis, has issued a press release to clarify the relationship between its research activities and those conducted by Quantumzyme LLP, a separate entity based in Bengaluru, India. The company emphasized that Quantumzyme LLP is not a subsidiary or affiliate of Quantum Genesis AI.
The clarification comes in response to prior press releases dated November 5, 2025, and February 12, 2026, which referenced scientific publications in the company's broader enzyme engineering and biocatalysis field. Those publications identified Quantumzyme LLP and reflected the affiliations of the contributing researchers at the time the research was conducted and submitted. The company now seeks to distinguish Quantumzyme LLP from Quantum Genesis AI and provide additional context regarding intellectual property and technology rights previously transferred to the company.
According to the press release, scientific publications arising from research activities undertaken by Quantum Genesis AI's Chief Executive Officer, Naveen Kulkarni, appropriately reflect the affiliations of the contributing researchers at the time the research was conducted and submitted. The company noted that Kulkarni transferred certain intellectual property, know-how, methodologies, processes, research and development materials, and related rights to the company pursuant to an Asset Purchase Agreement dated February 21, 2023. This agreement was further supported by a confirmatory assignment filed in the company's Current Report on Form 8-K on April 29, 2026.
The company believes that the Asset Purchase Agreement transferred underlying technology, methodologies, computational approaches, know-how, and related intellectual property associated with its core enzyme engineering and biocatalysis business. Consequently, to the extent that research activities conducted by Kulkarni, whether directly or through Quantumzyme LLP, relate to the company's core field and are based on or derived from the transferred technology platform, methodologies, know-how, or related intellectual property, the company believes such intellectual property and technology fall within the scope of the rights transferred to it.
This clarification is significant for investors and stakeholders as it delineates the boundaries of Quantum Genesis AI's intellectual property assets and addresses potential confusion about the ownership of research outputs. The company's prior disclosures regarding scientific publications were made on the basis of its ownership of the relevant intellectual property and technology. By clarifying these relationships, Quantum Genesis AI aims to maintain transparency and responsible corporate governance, which is crucial for investor confidence and regulatory compliance.
For more information, visit the company's website at https://qgaicorp.com/ and its profile on OTC Markets at https://www.otcmarkets.com/stock/QGAI.
